Emerging therapies for small cell lung cancer

Currently, chemotherapy remains the standard treatment for first- and second-line management of small cell lung cancer (SCLC). Immunotherapy has made progress in the treatment of SCLC, and nivolumab, pembrolizumab, atezolizumab, and durvalumab have led to significant improvements in clinical outcome...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of hematology and oncology Jg. 12; H. 1; S. 47 - 11
Hauptverfasser:	Yang, Sen, Zhang, Zhe, Wang, Qiming
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	London BioMed Central 02.05.2019 BioMed Central Ltd Springer Nature B.V BMC
Schlagworte:	Antineoplastic Combined Chemotherapy Protocols - pharmacology Antineoplastic Combined Chemotherapy Protocols - therapeutic use Cancer Research Cancer therapies Cancer treatment Carboplatin Care and treatment Chemotherapy Clinical trials Cytotoxicity Drug dosages Hematology Humans Immunotherapy Immunotherapy - methods Ipilimumab Lung cancer Lung Neoplasms - drug therapy Lung Neoplasms - pathology Medical prognosis Medicine Medicine & Public Health Metastasis Methods Monoclonal antibodies Neutropenia Oncology Orphan drugs Pembrolizumab Review RNA polymerase Small cell lung cancer Small cell lung carcinoma Small Cell Lung Carcinoma - drug therapy Small Cell Lung Carcinoma - pathology Targeted cancer therapy Targeted therapy China Small cell lung cancer Chemotherapy Targeted therapy Immunotherapy
ISSN:	1756-8722, 1756-8722
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!